Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

Preoperative or postoperative therapy for stage II or III rectal cancer: an updated practice guideline.

Wong RK, Berry S, Spithoff K, Simunovic M, Chan K, Agboola O, Dingle B; Gastrointestinal Cancer Disease Site Group.

Clin Oncol (R Coll Radiol). 2010 May;22(4):265-71. doi: 10.1016/j.clon.2010.03.002.

PMID:
20398849
2.

Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline.

Malthaner R, Wong RK, Spithoff K; Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

Clin Oncol (R Coll Radiol). 2010 May;22(4):250-6. doi: 10.1016/j.clon.2010.02.005.

PMID:
20398848
3.

[Systematic review: value of perioperative chemotherapy in the management of resectable rectal adenocarcinoma (brief report)].

Bécouarn Y, Guillo S, Artru P, Assenat E, Bosset JF, Conroy T, François E, Taïeb J, Touboul E.

Bull Cancer. 2008 Jul-Aug;95(7):717-34. Review. French.

4.

The use of preoperative radiotherapy in the management of patients with clinically resectable rectal cancer: a practice guideline.

Figueredo A, Zuraw L, Wong RK, Agboola O, Rumble RB, Tandan V; Cancer Care Ontario's Program in Evidence-based Care's Gastrointestinal Cancer Disease Site Group.

BMC Med. 2003 Nov 24;1:1. Review.

5.

Chemotherapy with preoperative radiotherapy in rectal cancer.

Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921.

N Engl J Med. 2006 Sep 14;355(11):1114-23. Erratum in: N Engl J Med. 2007 Aug 16;357(7):728.

6.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
7.

Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.

Chan AK, Wong A, Jenken D, Heine J, Buie D, Johnson D.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):665-77.

PMID:
15708244
8.

A systematic overview of radiation therapy effects in rectal cancer.

Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallin-Ståhl E.

Acta Oncol. 2003;42(5-6):476-92. Review.

PMID:
14596508
9.

Preoperative "chemoradiation" for stages II and III rectal carcinoma.

Stryker SJ, Kiel KD, Rademaker A, Shaw JM, Ujiki GT, Poticha SM.

Arch Surg. 1996 May;131(5):514-8; discussion 518-9.

PMID:
8624198
10.

[Local recurrence and survival rate after rectal cancer operations and multimodal therapy].

Thomschke D, Kyau-Ummen B, Halbfass HJ.

Chirurg. 2002 Mar;73(3):245-54. German.

PMID:
11963499
11.

[Practical neoadjuvant and adjuvant therapies for rectal cancer. How many patients are actually recruited in multimodality therapy concepts? An analysis of the Tumour Centre Schwerin].

Sauer J, Sobolewski K, Dommisch K.

Zentralbl Chir. 2009 Sep;134(5):450-4. doi: 10.1055/s-0028-1098930. Epub 2009 Sep 15. German.

PMID:
19757345
12.

[Established data and practical recommendations concerning pre- and postoperative chemotherapy of rectal cancer].

Rougier P, Mitry E, Clavéro-Fabri MC, Penna C, Nordlinger B.

Ann Chir. 1999;53(10):1011-8. Review. French.

PMID:
10670150
13.

Five fractions of preoperative radiotherapy for selected cases of rectal carcinoma: long-term tumor control and tolerance to treatment.

Myerson RJ, Genovesi D, Lockett MA, Birnbaum E, Fleshman J, Fry R, Kodner I, Menteer J, Picus J, Read T, Walz B.

Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):537-43.

PMID:
10078634
14.

Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.

Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M.

Dis Colon Rectum. 2004 Nov;47(11):1798-807.

PMID:
15622571
15.

Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?

Lombardi R, Cuicchi D, Pinto C, Di Fabio F, Iacopino B, Neri S, Tardio ML, Ceccarelli C, Lecce F, Ugolini G, Pini S, Di Tullio P, Taffurelli M, Minni F, Martoni A, Cola B.

Ann Surg Oncol. 2010 Mar;17(3):838-45. doi: 10.1245/s10434-009-0796-7. Epub 2009 Dec 12.

PMID:
20012700
16.

Response to preoperative chemoradiation in stage II and III rectal cancer.

Brown CL, Ternent CA, Thorson AG, Christensen MA, Blatchford GJ, Shashidharan M, Haynatzki GR.

Dis Colon Rectum. 2003 Sep;46(9):1189-93.

PMID:
12972962
17.

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.

J Clin Oncol. 2006 Sep 1;24(25):4062-8.

PMID:
16943523
18.
19.

A systematic overview of chemotherapy effects in colorectal cancer.

Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):282-308. Review.

PMID:
11441937
20.

Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis.

Malthaner RA, Wong RK, Rumble RB, Zuraw L; Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

BMC Med. 2004 Sep 24;2:35. Review.

Supplemental Content

Support Center